227 |
Plaque Progression and Regression |
James R. Margolis |
Sep. 29. 05 |
226 |
Evidence-Based Medicine Analysis of Current DES Clinical Use Guidelines: A Roadmap for Clinicians |
Gregg W. Stone |
Sep. 29. 05 |
225 |
Preventative Effects of Rosiglitazone on Restenosis after Coronary Stent Implantation |
Donghoon Choi |
Sep. 23. 05 |
224 |
The Promise of the Thiazolidinediones in the Management of Type 2 Diabetes-Associated Cardiovascular Disease |
Stephen Alistair Smith |
Sep. 23. 05 |
223 |
Inflammation: Novel Target for Cardiovascular Risk Reduction |
Andrew Zalewski |
Sep. 23. 05 |
222 |
Mechanisms Linking Angiotensin II & Atherogenesis |
Carlos M. Ferrario |
Sep. 23. 05 |
221 |
Beyond the Statin Therapy: The Importance of HDL Cholesterol |
Ki Hoon Han |
Sep. 23. 05 |
220 |
Early Statin Therapy in Acute Coronary Syndrome |
Cheol Whan Lee |
Sep. 23. 05 |
219 |
The TNT Trial: Is It Time to Shift Our Goals in Clinical Practice |
David Colquhoun |
Sep. 23. 05 |
218 |
Is Sirolimus Different from Analogues? |
Robert Falotico |
Sep. 14. 05 |